Yesterday (4/30) the FDA lifted some of the security requirements in the Drug Supply Chain Security Act to help expedite adequate distribution of prescription drugs due to COVID-19. These exemptions and exclusions apply to drugs in the supply chain under the Emergency Use Authorization (EUA) that are approved to help treat, cure, diagnose, or prevent COVID-19. The FDA wrote in their announcement, “…trading partners in most circumstances remain obligated to take appropriate steps when suspect or illegitimate products are found to ensure that these products are not further distributed and do not reach patients.”
Read more here.
More on: News Regulatory